NASDAQ: LTRN - Lantern Pharma Inc.

Altı ay boyunca karlılık: +0.5714%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Lantern Pharma Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

daha fazla ayrıntı
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2020-06-11
ISIN US51654W1018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lanternpharma.com
Цена ао 3.65
Günlük fiyat değişimi: -0.2833% (3.53)
Haftalık fiyat değişimi: +36.43% (2.58)
Aylık fiyat değişimi: -7.37% (3.8)
3 ayda fiyat değişimi: +0.8596% (3.49)
Altı ayda fiyat değişimi: +0.5714% (3.5)
Yıllık fiyat değişimi: -41.04% (5.97)
3 yılda fiyat değişimi: -47.7% (6.73)
Yılbaşından bu yana fiyat değişimi: +16.56% (3.02)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 1.08 9
P/E 0 0
EV/EBITDA -1.27 0
Toplam: 3.63

Yeterlik

İsim Anlam Seviye
ROA, % -36.57 0
ROE, % -39.02 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0132 10
Toplam: 9.6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 557.78 10
karlılık EPS, % 276.99 10
Toplam: 8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Vanguard Group Inc 365334 3.4
NewEdge Advisors, LLC 165972 1.55
Geode Capital Management, LLC 95036 0.88
CM Management, LLC 80000 0.74
Carlson Capital. L.P. 60000 0.56
Commonwealth Equity Services, LLC 58848 0.55
Renaissance Technologies, LLC 43800 0.41
Redmond Asset Management, LLC 40662 0.38
Horizon Kinetics Asset Management LLC 28791 0.27
State Street Corporation 27752 0.26



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Panna Sharma PH.D. President, CEO & Director 684.38k 1971 (54 yıl)
Mr. David R. Margrave CFO & Secretary 442.68k 1961 (64 yıl)
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 283.24k 1955 (70 yıllar)
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor N/A
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations N/A
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics

Adres: United States, Dallas. TX, 1920 McKinney Avenue - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.lanternpharma.com